Trial Profile
A Phase 3 Safety and Efficacy Study of Vitreosolve® for Four Ophthalmic Intravitreal Injections For Inducing Posterior Vitreous Detachment in Retinopathy Patients.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Vitreosolve (Primary)
- Indications Diabetic retinopathy
- Focus Registrational; Therapeutic Use